Eli Lilly and Company (LLY) News



Eli Lilly and Company (LLY)

Today's Latest Price: $206.14 USD

3.79 (1.87%)

Updated Jan 22 7:00pm

Add LLY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

StocksNews Articles for LLY

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest LLY News From Around the Web

Below are the latest news stories about ELI LILLY & Co that investors may wish to consider to help them evaluate LLY as an investment opportunity.

Antibody can prevent COVID-19 infection in nursing, LTC homes: drugmaker Eli Lilly

The study, which was conducted with the National Institutes of Health, is the first major one to show such a treatment may prevent illness in a group devastated by the pandemic.

Global News Canada | January 21, 2021

LIVE: Jim Cramer on Amazon, Eli Lilly, Fuelcell, FAANG, Stock Market Thursday

In Thursday's market breakdown, Jim Cramer talks airlines, Amazon, Eli Lilly, Fuelcell and more.

The Street | January 21, 2021

Eli Lilly Says Covid-19 Treatment Reduces Risk for Nursing Home Residents

Eli Lilly says nursing home residents have an 80% lower risk of contracting Covid-19 compared with those who received a placebo.

The Street | January 21, 2021

Women Health Market Impressive Growth 2021 to 2027 | Sanofi, Amgen, Eli Lilly and Company, Lupin Pharmaceuticals

The key market drivers for Women Health Market Includes, Increasing awareness about women health along with various R&D activities by research companies for proving better therapeutics and health care to women. Moreover, changes in lifestyle which leads to bad nutrition

OpenPR | January 21, 2021

Latest study shows Eli Lilly’s (LLY) antibody reduces COVID-19 by 80%

Eli Lilly and Company (NYSE: LLY) announced that the results from its latest study indicated that its monoclonal antibody bamlanivimab reduced the risk of contracting COVID-19 significantly in nursing homes. […] The post Latest study shows Eli Lilly’s (LLY) antibody reduces COVID-19 by 80% first appeared on AlphaStreet .

AlphaStreet | January 21, 2021

Testosterone Replacement Therapy Market 2021 Research Report, Latest Trend, Demands, Industry Growth, Size, Share, Top Key Players And Forecast 2027 | Allergan plc, Eli Lilly and Company, Endo Pharmaceuticals, Mylan N.V.

Allied Market Research published a new report, titled, "Testosterone Replacement Therapy Market Global Opportunity Analysis and Industry Forecast, 2020-2027". The report has offered an all-inclusive analysis of the global Testosterone Replacement Therapy Market taking into consideration all the crucial aspects like

OpenPR | January 21, 2021

STAT+: Pharmalittle: Lilly says its antibody prevented Covid-19 in a trial; EU and Pfizer clash over vaccine delays

Eli Lilly says its monoclonal antibody prevented Covid-19 infections in nursing home residents and staff in a clinical trial, the first time such a treatment has been shown to prevent…

STAT News | January 21, 2021

Lilly: Drug can prevent COVID-19 illness in nursing homes

Drugmaker Eli Lilly says its COVID-19 antibody drug can prevent illness among residents and staff of nurusing homes and other long-term care locations

ABC News | January 21, 2021

Eli Lilly antibody cuts COVID-19 risk up to 80% in nursing home study

Eli Lilly’s antibody therapy reduced nursing home residents’ risk of symptomatic COVID-19 by as much as 80% when used preventively in a study and also significantly reduced the risk of symptomatic disease in nursing home workers

The Star | January 21, 2021

Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-19, drugmaker reports

A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut risk of COVID-19 by up to 80%, maker Eli Lilly announced.

USA Today | January 21, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.596 seconds.